Summary
0A88 Chart
10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Adam Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Madeline Mollman Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lu Li - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jaden Rismay - JPMorgan Chase & Co, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the 10X Genomics' Third Quarter 2025 Earnings Conference Call.
Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.
10x Genomics Inc. (0A88) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has 10x Genomics Inc. ever had a stock split?
10x Genomics Inc. Profile
| Life Sciences Tools & Services Industry | Healthcare Sector | Serge Saxonov CEO | LSE Exchange | US88025U1097 ISIN |
| US Country | 1,306 Employees | - Last Dividend | 17 Jul 2006 Last Split | 12 Sep 2019 IPO Date |
Overview
10x Genomics, Inc. is a prominent life science technology company known for its innovative development and commercialization of instruments, consumables, and software aimed at analyzing biological systems. The company's footprint extends across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific regions, catering to a diverse clientele that includes academic, government, biopharmaceutical, biotechnology, and other institutions. Originally named 10X Technologies, Inc., it underwent a rebranding to 10x Genomics, Inc. in November 2014. Since its inception in 2012, 10x Genomics has established its headquarters in Pleasanton, California, positioning itself as a leader in the field of genomics and cellular analysis.
Products and Services
- Chromium Instruments: This product line includes the chromium, chromium connect, and chromium controller instruments. These are cornerstone tools for 10x Genomics, facilitating a range of single cell solutions that enable researchers to delve into the intricacies of gene activity and networks on a cell-by-cell basis. The chromium instruments are complemented by microfluidic chips, slides, reagents, and other essential consumables.
- Single Cell Solutions:
- Single Cell Gene Expression: This solution measures gene activity and networks at the individual cell level, providing detailed insights into cellular functions.
- Single Cell Immune Profiling: Targeted at studying the immune system, this solution offers a detailed look at immune cell interactions and functions.
- Single Cell Assay for Transposase Accessible Chromatin (ATAC): Designed to explore the epigenetic landscape of cells, this solution unveils how the accessibility of chromatin influences gene expression.
- Single Cell Multiome ATAC + Gene Expression: This solution allows for the simultaneous investigation of RNA and chromatin accessibility within a single cell, presenting a comprehensive view of cellular function.
- Visium Platform: The Visium platform represents a revolutionary step in tissue analysis, providing researchers with the ability to understand the spatial positioning of biological analytes within tissues at high resolutions. This is crucial for comprehending the complex interplay between cellular components in various biological and pathological states.
- Xenium Platform: Geared towards in situ analysis, the Xenium platform offers an innovative method for analyzing molecular and cellular biology directly within tissue samples. This approach is pivotal for advancing our understanding of complex biological systems and diseases.
Contact Information
